LAVAL, QC and ALPHARETTA, Ga.—Bausch + Lomb, a global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) and Clearside Biomedical, Inc. (Nasdaq: CLSD) announced Monday that the U.S. Food and Drug Administration (FDA) has approved the drug Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with uveitis, a form of eye inflammation. "With this FDA approval, Xipere is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, which is the leading cause of vision loss in people with uveitis," said Joseph C. Papa, chairman and CEO, Bausch Health. Read More